tradingkey.logo

BRIEF-EMA's CHMP Says Opinion Recommending Marketing Authorisation For Leqembi Not Need To Be Updated

ReutersFeb 28, 2025 12:44 PM

- EMA's CHMP:

  • EMA'S CHMP: VYJUVEK (BEREMAGENE GEPERPAVEC) RECEIVE POSITIVE OPINION TO TREAT WOUNDS IN PATIENTS OF ALL AGES WITH DYSTROPHIC EPIDERMOLYSIS BULLOSA

  • EMA SAYS CHMP: CONCLUDED THAT ITS OPINION RECOMMENDING MARKETING AUTHORISATION FOR LEQEMBI (LECANEMAB) DOES NOT NEED TO BE UPDATED

  • EMA'S CHMP: EXTENSION TO EXISTING INDICATION OF CHIKUNGUNYA VACCINE IXCHIQ TO INCLUDE ACTIVE IMMUNISATION OF ADOLESCENTS FROM 12 YEARS OF AGE

  • EMA'S CHMP: FABHALTA GETS POSITIVE OPINION FOR EXTENSION OF INDICATION FOR TREATMENT OF ADULT PATIENTS WITH COMPLEMENT 3 GLOMERULOPATHY

  • EMA'S CHMP: RECOMMENDS APPROVAL OF DEQSIGA FOR PRIMARY, SECONDARY IMMUNODEFICIENCIES AND AUTOIMMUNE DISEASE IMMUNOMODULATION

Source text: [ID:]

Further company coverage: KRYS.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI